IMNM Stock Analysis: Immunome | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.397m USD | 12M Return: 26.7% | US45257U1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.9M
Qual. Beats: -1
Rev. Trend: -99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Immunome, Inc. (NASDAQ: IMNM) is a U.S.-based biotechnology company headquartered in Bothell, Washington, founded in 2006. The company focuses on discovering, developing, and commercializing antibody-drug conjugates (ADCs) and other oncology therapeutics.
Its lead clinical asset, Varegacestat, is a gamma secretase inhibitor currently in a Phase 3 trial for desmoid tumors. The pipeline also includes IM-1021, a ROR1-targeted ADC in Phase 1, and a preclinical portfolio featuring IM-3050, a fibroblast activation protein (FAP)-directed radioligand therapy, along with solid tumor ADC candidates IM-1617, IM-1340, and IM-1335. Immunome went public on NASDAQ in October 2020 and is classified as a mid-cap stock in the Health Care sector.
As an oncology-focused biotech, Immunome operates within a research-intensive segment where revenue is typically dependent on clinical trial outcomes, regulatory milestones, and partnership or licensing agreements rather than commercial product sales. ADCs and radioligand therapies represent an active area of oncology drug development, with multiple large-cap pharmaceutical companies pursuing similar targeting strategies.
- Varegacestat Phase 3 desmoid tumor data readout approaches
- ADC pipeline advances with IM-1021 Phase 1 progress
- Cash burn widens as clinical trial enrollment accelerates
| Net Income: -254.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 24.08 > 1.0 |
| NWC/Revenue: 7.24k% < 20% (prev 2.02k%; Δ 5.22k% < -1%) |
| CFO/TA -0.37 > 3% & CFO -208.8m > Net Income -254.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.3m) vs 12m ago 30.18% < -2% |
| Gross Margin: 57.43% > 18% (prev 79.25%; Δ -21.82% > 0.5%) |
| Asset Turnover: 1.61% > 50% (prev 4.25%; Δ -2.64% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 538.4m - Total Current Liabilities 35.7m) / Total Assets 565.4m |
| B: -1.51 (Retained Earnings -855.1m / Total Assets 565.4m) |
| C: -0.59 (EBIT TTM -254.3m / Avg Total Assets 430.8m) |
| D: 13.03 (Book Value of Equity 525.1m / Total Liabilities 40.3m) |
| Altman-Z'' = 10.62 = AAA |
As of November 05, 2026, the stock is trading at USD 19.52 with a total of 3,321,760 shares traded. Over the past week, the price has changed by +4.05%, over one month by -7.79%, over three months by -22.11% and over the past year by +26.67%.
Current recommended Stop Loss: 18.20 (which is 6.8% or 1.3 ATR below the current price).
Immunome has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy IMNM.
- StrongBuy: 13
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.3 | 81% |
P/S = 791.7903
P/B = 4.4003
Revenue TTM = 6.94m USD
EBIT TTM = -254.3m USD
EBITDA TTM = -250.9m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 4.59m USD (from shortLongTermDebtTotal, last quarter) (leases 4.74m already included)
Net Debt = -515.4m USD (calculated: Debt 4.59m - CCE 520.0m)
Enterprise Value = 1.88b USD (2.40b + Debt 4.59m - CCE 520.0m)
Interest Coverage Ratio = unknown (Ebit TTM -254.3m / Interest Expense TTM 0.0)
EV/FCF = -8.59x (Enterprise Value 1.88b / FCF TTM -219.1m)
FCF Yield = -11.65% (FCF TTM -219.1m / Enterprise Value 1.88b)
FCF Margin = -3.16k% (FCF TTM -219.1m / Revenue TTM 6.94m)
Net Margin = -3.66k% (Net Income TTM -254.3m / Revenue TTM 6.94m)
Gross Margin = 57.43% ((Revenue TTM 6.94m - Cost of Revenue TTM 2.96m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.33 (Enterprise Value 1.88b / Total Assets 565.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.59m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -200.9m (EBIT -254.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.08 (Total Current Assets 538.4m / Total Current Liabilities 35.7m)
Debt / Equity = 0.01 (Debt 4.59m / totalStockholderEquity, last quarter 525.1m)
Debt / EBITDA = 2.05 (negative EBITDA) (Net Debt -515.4m / EBITDA -250.9m)
Debt / FCF = 2.35 (negative FCF - burning cash) (Net Debt -515.4m / FCF TTM -219.1m)
Total Stockholder Equity = 503.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.03% (Net Income -254.3m / Total Assets 565.4m)
RoE = -50.56% (Net Income TTM -254.3m / Total Stockholder Equity 503.0m)
RoCE = -48.02% (EBIT -254.3m / Capital Employed (Total Assets 565.4m - Current Liab 35.7m))
RoIC = -37.96% (negative operating profit) (NOPAT -200.9m / Invested Capital 529.3m)
WACC = 9.53% (E(2.40b)/V(2.40b) * Re(9.55%) + D(4.59m)/V(2.40b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.45 | Cagr: 190.2%
[DCF] Fair Price = unknown (Cash Flow -219.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.12 | # QB: -1
Revenue Correlation: -98.99 | Revenue CAGR: -29.63% | SUE: -0.11 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.60 | Chg30d=-1.62% | Revisions=-31% | Analysts=15
EPS current Year (2026-12-31): EPS=-2.33 | Chg30d=-1.62% | Revisions=-25% | GrowthEPS=+4.2% | GrowthRev=-96.2%
EPS next Year (2027-12-31): EPS=-2.46 | Chg30d=-1.31% | Revisions=-55% | GrowthEPS=-5.6% | GrowthRev=+18804.0%
[Analyst] Revisions Ratio: -50% (up=4, down=15)